<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACTIMMUNE- interferon gamma-1b injection, solution </strong><br>HZNP USA, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ACTIMMUNE<span class="Sup">®</span> safely and effectively.  See full prescribing information for ACTIMMUNE.<br><br>ACTIMMUNE<span class="Sup">®</span> (interferon gamma-1b) injection, for subcutaneous use<br>Initial U.S. Approval: 1990</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ACTIMMUNE is an interferon gamma indicated for: </p>
<ul class="Disc">
<li>Reducing the frequency and severity of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> associated with <span class="product-label-link" type="condition" conceptid="4300478" conceptname="Chronic granulomatous disease">Chronic Granulomatous Disease</span> (CGD)  (<a href="#S1">1</a>)</li>
<li>Delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO) (<a href="#S1">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>For subcutaneous use only (<a href="#S2.1">2.1</a>)</li>
<li>The recommended dose is 50 mcg/m<span class="Sup">2</span> for patients whose body surface area is greater than 0.5 m<span class="Sup">2</span> and 1.5 mcg/kg/dose for patients whose body surface area is equal to or less than 0.5 m<span class="Sup">2</span> three times weekly. (<a href="#S2.1">2.1</a>)</li>
<li>Monitor hematology, blood chemistries and urinalysis prior to the beginning of treatment and at 3-month intervals. (<a href="#S2.1">2.1</a>)</li>
<li>If severe reactions occur, reduce dose by 50 percent or discontinue therapy until the adverse reaction abates. (<a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection<span class="Bold">:</span> 100 mcg (2 million International Units) of Interferon gamma-1b in 0.5 mL solution in a single use vial. (<a href="#S3">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to interferon gamma, <span class="Italics">E. coli</span> derived products, or any component of the product (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span>: Pre-existing cardiac conditions may be exacerbated. (<a href="#S5.1">5.1</a>)</li>
<li>
<span class="Italics">Neurologic Disorders</span>: Reduce dose or discontinue if decreased mental status, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> occur. (<a href="#S5.2">5.2</a>) </li>
<li>
<span class="Italics">Bone Marrow Toxicity</span>: Monitor for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> particularly when administering ACTIMMUNE in combination with other potentially myelosuppressive agents. (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Italics">Hepatic Toxicity</span>: Reduce dose or discontinue to reverse severe elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT); monitor liver function monthly in patients less than 1 year old. (<a href="#S5.4">5.4</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:  </span>If serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur, discontinue and institute appropriate medical therapy. (<a href="#S5.5">5.5</a>)</li>
<li>
<span class="Italics">Renal Toxicity</span>: Monitor renal function regularly when administering ACTIMMUNE to patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Common adverse reactions (incidence rate 2% or greater) for ACTIMMUNE include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#S6">6</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma USA, Inc. at 1-866-479-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span><span class="Bold Italics">.</span> </p></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li> Concomitant use of drugs with neurotoxic, hematotoxic or cardiotoxic effects may increase the toxicity of interferons. (<a href="#S7.2">7.2</a>)</li>
<li> Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (e.g., vaccines). (<a href="#S7.3">7.3</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Based on animal data, may cause fetal harm. (<a href="#S8.1">8.1</a>) </p></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Important Administration Instructions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dose Modification</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Neurologic Disorders</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Bone Marrow Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Hepatic Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Renal Toxicity</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> to Natural Rubber</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Immunogenicity</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 	Myelosuppressive Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Drugs with Neurotoxic, Hematoxic or Cardiotoxic Effects</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Immunological Preparations</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Effects on Cytochrome P-450 Pathways</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2	Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.3	Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Effects in <span class="product-label-link" type="condition" conceptid="4300478" conceptname="Chronic granulomatous disease">Chronic Granulomatous Disease</span> (CGD)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Effects in Severe, Malignant Osteopetrosis (SMO)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2	Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<ul class="Disc">
<li>ACTIMMUNE is indicated for reducing the frequency and severity of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> associated with <span class="product-label-link" type="condition" conceptid="4300478" conceptname="Chronic granulomatous disease">Chronic Granulomatous Disease</span> (CGD).</li>
<li>ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dosing Information</h2>
<ul class="Disc"><li>The recommended dosage of ACTIMMUNE administered subcutaneously, for the treatment of patients with CGD and SMO is shown in Table 1 below:</li></ul>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Recommended Dosage for ACTIMMUNE for the Treatment of Patients with CGD and SMO</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Body Surface Area (m<span class="Sup">2</span>)</th>
<th class="Rrule" align="center">Dose (mcg/m<span class="Sup">2</span>)</th>
<th class="Rrule" align="center">Dose (International Units/m<span class="Sup">2</span>)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Frequency</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Note that the above activity is expressed in International Units (1 million International Units/50 mcg). This is equivalent to what was previously expressed as units (1.5 million units/50 mcg).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Greater than 0.5 m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">50 mcg/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">1 million International Units/m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">Three times weekly<br>(For example, Monday, Wednesday and Friday)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Equal to or less than 0.5 m<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">1.5 mcg/kg/dose</td>
<td class="Rrule" align="center">------------</td>
<td class="Rrule" align="center">Three times weekly<br>(For example, Monday, Wednesday and Friday)</td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Prior to the beginning of treatment and at three-month intervals during treatment the following laboratory tests are recommended for all patients on ACTIMMUNE (interferon gamma-1b) therapy<span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3</a>, <a href="#S5.4">5.4</a>, <a href="#S5.6">5.6)</a>]</span>: 						<ul class="Circle">
<li>Hematologic tests – including complete blood counts, differential and platelet counts</li>
<li>Blood chemistries – including renal and liver function tests. In patients less than 1 year of age, liver function tests should be measured monthly <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</li>
<li>Urinalysis</li>
</ul>
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Important Administration Instructions</h2>
<ul class="Disc">
<li>The optimum sites of subcutaneous injection are the right and left deltoid and anterior thigh.</li>
<li>ACTIMMUNE can be administered by a physician, nurse, family member or patient when appropriately counseled in the administration of subcutaneous injections.</li>
<li>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ACTIMMUNE is a clear, colorless solution.</li>
<li>ACTIMMUNE is for a single use only. Discard any unused portion. ACTIMMUNE does not contain a preservative.</li>
<li>ACTIMMUNE should not be mixed with other drugs in the same syringe.</li>
<li>Administer ACTIMMUNE using either sterilized glass or plastic disposable syringes.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dose Modification</h2>
<ul class="Disc">
<li>If severe reactions occur, the dosage should be reduced by 50 percent or therapy should be interrupted until the adverse reaction abates.</li>
<li>Safety and efficacy has not been established for ACTIMMUNE given in doses greater or less than the recommended dose of 50 mcg/m<span class="Sup">2</span>. Higher doses (i.e., greater than 50 mcg/m<span class="Sup">2</span>) are not recommended. The minimum effective dose of ACTIMMUNE has not been established.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Injection: 100 mcg (2 million International Units) per 0.5 mL solution in a single-use vial.  ACTIMMUNE (interferon gamma-1b) is a sterile, clear, colorless solution filled in a single-use vial for subcutaneous injection.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ACTIMMUNE is contraindicated in patients who develop or have known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to interferon gamma, <span class="Italics">E. coli </span>derived products, or any component of the product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">Acute and transient "flu-like" symptoms such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> induced by ACTIMMUNE at doses of 250 mcg/m<span class="Sup">2</span>/day (greater than 10 times the weekly recommended dose) or higher may exacerbate pre-existing cardiac conditions. Patients with pre-existing cardiac conditions, including <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> on ACTIMMUNE should be monitored for signs/symptoms of exacerbation. Some of the "flu-like" symptoms may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may also be used to ameliorate these effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Neurologic Disorders</h2>
<p class="First">Decreased mental status, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have been observed, particularly in patients receiving ACTIMMUNE doses greater than 250 mcg/m<span class="Sup">2</span>/day (greater than 10 times the weekly recommended dose). Most of these abnormalities were reversible within a few days upon dose reduction or discontinuation of therapy.  Monitor patients when administering ACTIMMUNE to patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or compromised central nervous system function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Bone Marrow Toxicity</h2>
<p class="First">Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that can be severe and may be dose related have been observed during ACTIMMUNE therapy. Monitor neutrophil and platelet counts in patients with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> during treatment with ACTIMMUNE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Hepatic Toxicity</h2>
<p class="First">Repeated administration of ACTIMMUNE to patients with advanced <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> may result in accumulation of interferon gamma-1b. Frequent assessment of liver function in these patients is recommended.</p>
<p>Elevations of aspartate transaminase (AST) and /or alanine transaminase (ALT) (up to 25-fold) have been observed during ACTIMMUNE therapy. The incidence appeared to be higher in patients less than 1 year of age compared to older children. The transaminase elevations were reversible with reduction in dosage or interruption of ACTIMMUNE treatment. Patients begun on ACTIMMUNE before age one year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Isolated cases of acute serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been observed in patients receiving ACTIMMUNE. If such an acute reaction develops the drug should be discontinued immediately and appropriate medical therapy instituted. Transient cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> have occurred in some patients following injection of ACTIMMUNE that have necessitated treatment interruption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Renal Toxicity</h2>
<p class="First">Monitor renal function regularly when administering ACTIMMUNE in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> because the possibility exists that with repeated administration, accumulation of interferon gamma-1b may occur. Renal toxicity has been reported in patients receiving ACTIMMUNE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> to Natural Rubber</h2>
<p class="First">The stopper of the glass vial for ACTIMMUNE contains natural rubber (a derivative of latex) which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described below and elsewhere in the warnings and precautions section of the labeling:</p>
<ul class="Disc">
<li><span class="Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> [see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span></li>
<li><span class="Italics">Neurologic Disorders [see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span></li>
<li><span class="Italics">Bone Marrow Toxicity [see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span></li>
<li><span class="Italics">Hepatic Toxicity [see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span></li>
<li><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> [see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span></li>
<li><span class="Italics">Renal Toxicity [see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span></li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The following data on adverse reactions are based on the subcutaneous administration of ACTIMMUNE at a dose of 50 mcg/m<span class="Sup">2</span>, three times weekly, in patients with CGD during a clinical trial in the United States and Europe.</p>
<p>The most common adverse reactions observed in patients with CGD are shown in the following table:</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Adverse Reactions Occurring in 2 % or Greater of CGD Patients Receiving ACTIMMUNE in Clinical Trials</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Adverse Reactions</th>
<th class="Rrule" align="center" colspan="2">Percent of Patients</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">ACTIMMUNE<br>CGD (n=63)</th>
<th class="Rrule" align="center">Placebo<br>CGD (n=65)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">28</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>Similar safety data were observed in 34 patients with SMO.</p>
<p>The clinical and laboratory toxicity associated with multiple dose studies of ACTIMMUNE is dose, route and schedule-dependent.</p>
<p>The most common adverse reactions include constitutional symptoms such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> which may decrease in severity as treatment continues.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Less Common Adverse Reactions </span></span></p>
<p>The following adverse reactions are assessed as potentially related to ACTIMMUNE (interferon gamma-1b) therapy:</p>
<p>Blood and Lymphatic System—<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (reversible), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>Cardiovascular— <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive cardiac failure</span>), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, (acute) <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Gastrointestinal—<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">granulomatous colitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> with fatal outcome.</p>
<p>General Disorders and Administration Site Conditions—<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness/flu-like symptoms, <span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">injection site hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p>Hepatobiliary Disorders—<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>.</p>
<p>Immunological—<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, increased autoantibodies, lupus-like syndrome (including <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>-flares and drug-induced <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>), and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and Infestations—<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>.</p>
<p>Investigations—blood alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span>/ elevation of hepatic enzymes, increased triglycerides, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>.</p>
<p>Metabolic—<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.</p>
<p>Musculoskeletal—<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4279382" conceptname="Clubbing">clubbing</span>, and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>.</p>
<p>Nervous System—<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>), <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, Parkinsonian symptoms, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (including <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal convulsions</span>), and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>.</p>
<p>Psychiatric—<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>, and mental status decreased.</p>
<p>Pulmonary—<span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>.</p>
<p>Renal—<span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (which may be reversible) and <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.</p>
<p>Skin and Subcutaneous Tissue Disorders—<span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, (exacerbation of) <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, transient cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Vascular Disorder—deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p>Abnormal Laboratory Test Values:  Elevations of ALT and AST have been observed <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of ACTIMMUNE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Underline">Children with CGD less than 3 years of age:</span></p>
<p>Data on the safety and activity of ACTIMMUNE in 37 patients under the age of 3 years was pooled from four uncontrolled postmarketing studies. The rate of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> per patient-year in this uncontrolled group was similar to the rate observed in the ACTIMMUNE treatment groups in controlled trials. Developmental parameters (height, weight and endocrine maturation) for this uncontrolled group conformed to national normative scales before and during ACTIMMUNE therapy.</p>
<p>In 6 of the 10 patients receiving ACTIMMUNE therapy before age one year 2-fold to 25-fold elevations from baseline of AST and/or ALT were observed. These elevations occurred as early as 7 days after starting treatment. Treatment with ACTIMMUNE was interrupted in all 6 of these patients and was restarted at a reduced dosage in 4. Liver transaminase values returned to baseline in all patients and transaminase elevation recurred in one patient upon ACTIMMUNE rechallenge. An 11-fold alkaline phosphatase elevation and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in one patient and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC = 525 cells/mm<span class="Sup">3</span>) in another patient resolved with interruption of ACTIMMUNE treatment and did not recur with rechallenge.</p>
<p>In the postmarketing safety database clinically significant adverse reactions observed during ACTIMMUNE therapy in children under the age of three years (n=14) included: two cases of <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, and one case each of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">granulomatous colitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is a potential for immunogenicity. In clinical trials, 8 out of 33 ACTIMMUNE-treated patients developed non-neutralizing antibodies to interferon gamma-1b. No neutralizing antibodies to ACTIMMUNE have been detected in patients. In a Phase 1 study, none of the 38 ACTIMMUNE-treated healthy volunteers developed non-neutralizing antibodies to interferon gamma-1b.</p>
<p>The detection of antibody formation, including neutralizing antibody, in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ACTIMMUNE with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 	Myelosuppressive Agents</h2>
<p class="First">When administering ACTIMMUNE in combination with other potentially myelosuppressive agents, monitor neutrophil and platelet counts <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Drugs with Neurotoxic, Hematoxic or Cardiotoxic Effects</h2>
<p class="First">The concurrent use of drugs having neurotoxic (including effects on the central nervous system), hematotoxic, or cardiotoxic effects may increase the toxicity of interferons in these systems. It is theoretically possible that hepatotoxic and/or nephrotoxic drugs might have an effect on the clearance of ACTIMMUNE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Immunological Preparations</h2>
<p class="First">Simultaneous administration of ACTIMMUNE with other heterologous serum protein preparations or immunological preparations (e.g., vaccines) should be avoided due to the risk of an unexpected, or amplified, immune response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Effects on Cytochrome P-450 Pathways</h2>
<p class="First">Preclinical studies in rodents using species-specific interferon gamma have demonstrated a decrease in hepatic microsomal cytochrome P-450 concentrations. This could potentially lead to a <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the hepatic metabolism of certain drugs that utilize this degradative pathway.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. ACTIMMUNE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>ACTIMMUNE has shown an increased incidence of abortions in primates when given from gestation day 20 to 80 in doses approximately 100 times the human dose. A study in pregnant primates treated with subcutaneous doses 2–100 times the human dose failed to demonstrate teratogenic activity for ACTIMMUNE.</p>
<p>Female mice treated subcutaneously with recombinant murine IFN-interferon gamma (rmuIFN-gamma) at 280 times the maximum recommended clinical dose of ACTIMMUNE from shortly after birth through puberty but not during pregnancy had offspring which exhibited decreased body weight during the lactation period. The clinical significance of this finding observed following treatment of mice with rmuIFN-gamma is uncertain. For lower doses, there is no evidence of maternal toxicity, embryotoxicity, fetotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in preclinical studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="77290-5">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2	Lactation</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>It is not known whether ACTIMMUNE is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ACTIMMUNE, a decision should be made whether to discontinue nursing or to discontinue the drug, dependent upon the importance of the drug to the mother.</p>
</div>
</div>
<div class="Section" data-sectionCode="77291-3">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3	Females and Males of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p>Based on the information available, it cannot be excluded that the presence of higher levels of interferon gamma may impair male fertility and that in certain cases of <span class="product-label-link" type="condition" conceptid="197606" conceptname="Female infertility of tubal origin">female infertility</span> increased levels of interferon gamma may have played a role [<span class="Italics">see <a href="#S13.1">Nonclinical Toxicology (13.1)</a></span>].</p>
<p>In younger patients, the long-term effect on fertility is also not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of ACTIMMUNE has been established in pediatric patients aged 1 year and older in CGD patients and 1 month and older in SMO patients <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]. </span>There are no data available for pediatric patients below the age of 1 month.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of ACTIMMUNE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Central nervous system adverse reactions including decreased mental status, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have been observed, particularly in patients receiving doses greater than 100 mcg/m<span class="Sup">2</span>/day by intravenous or intramuscular administration. These abnormalities were reversible within a few days upon dose reduction or discontinuation of therapy. Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, elevation of hepatic enzymes and of triglycerides, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have also been observed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ACTIMMUNE (Interferon gamma-1b), an interferon gamma, is a single-chain polypeptide containing 140 amino acids. Production of ACTIMMUNE is achieved by fermentation of a genetically engineered <span class="Italics">Escherichia coli</span> bacterium containing the DNA which encodes for the recombinant protein. Purification of the product is achieved by conventional column chromatography. ACTIMMUNE is a highly purified sterile solution consisting of non-covalent dimers of two identical 16,465 Dalton monomers; with a specific activity of 20 million International Units/mg (2×10<span class="Sup">6</span> International Units/0.5 mL) which is equivalent to 30 million units/mg.</p>
<p>ACTIMMUNE is a sterile, clear, colorless solution filled in a single-use vial for subcutaneous injection. Each 0.5 mL of ACTIMMUNE contains: 100 mcg (2 million International Units) of interferon gamma-1b formulated in disodium succinate hexahydrate (0.37 mg), mannitol (20 mg), polysorbate 20 (0.05 mg), succinic acid (0.14 mg) and Sterile Water for Injection. Note that the above activity is expressed in International Units (1 million International Units/50 mcg). This is equivalent to what was previously expressed as units (1.5 million units/50 mcg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Interferons bind to specific cell surface receptors and initiate a sequence of intracellular events that lead to the transcription of interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind to the alpha/ beta receptor. Interferon gamma binds to a different cell surface receptor and is classified as Type 2 interferon. Specific effects of interferon gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), activation of natural killer (NK) cells, and the expression of Fc receptors and major histocompatibility antigens.</p>
<p>CGD is an inherited disorder of leukocyte function caused by defects in the enzyme complex responsible for phagocyte superoxide generation. ACTIMMUNE does not increase phagocyte superoxide production even in treatment responders.</p>
<p>In SMO (an inherited disorder characterized by an osteoclast defect, leading to bone overgrowth, and by deficient phagocyte oxidative metabolism), a treatment-related enhancement of superoxide production by phagocytes was observed. ACTIMMUNE was found to enhance osteoclast function in vivo.</p>
<p>In both disorders, the exact mechanism(s) by which ACTIMMUNE has a treatment effect has not been established. Changes in superoxide levels during ACTIMMUNE therapy do not predict efficacy and should not be used to assess patient response to therapy.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Pharmacokinetic studies in patients with CGD have not been performed. The intravenous, intramuscular, and subcutaneous pharmacokinetics of ACTIMMUNE have been investigated in 24 healthy male subjects following single-dose administration of 100 mcg/m<span class="Sup">2</span> (twice the recommended dose for CGD and SMO patients). ACTIMMUNE is rapidly cleared after intravenous administration (1.4 Liters/minute) and slowly absorbed after intramuscular or subcutaneous injection. After intramuscular or subcutaneous injection, the apparent fraction of dose absorbed was greater than 89%. The mean elimination half-life after intravenous administration of 100 mcg/m<span class="Sup">2</span> in healthy male subjects was 38 minutes. The mean elimination half-lives for intramuscular and subcutaneous dosing with 100 mcg/m<span class="Sup">2</span> were 2.9 and 5.9 hours, respectively. Peak plasma concentrations, determined by ELISA, occurred approximately 4 hours (1.5 ng/mL) after intramuscular dosing and 7 hours (0.6 ng/mL) after subcutaneous dosing. Multiple dose subcutaneous pharmacokinetic studies were conducted in 38 healthy male subjects. There was no accumulation of ACTIMMUNE after 12 consecutive daily injections of 100 mcg/m<span class="Sup">2</span>.</p>
<p>Interferon gamma was not detected in the urine of healthy human volunteers following administration of 100 mcg/m<span class="Sup">2</span> of ACTIMMUNE by the intravenous, intramuscular and subcutaneous routes. In vitro perfusion studies utilizing rabbit livers and kidneys demonstrate that these organs are capable of clearing interferon gamma from perfusate.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis:</span>  ACTIMMUNE has not been tested for its carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis:</span>  Ames tests using five different tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of bacteria with and without metabolic activation revealed no evidence of mutagenic potential. ACTIMMUNE was tested in a micronucleus assay for its ability to induce chromosomal damage in bone marrow cells of mice following two intravenous doses of 20 mg/kg. No evidence of chromosomal damage was noted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span>:  Female cynomolgus monkeys treated with daily subcutaneous doses of 30 or 150 mcg/kg ACTIMMUNE (approximately 20 and 100 times the human dose) exhibited <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> or absence of cyclicity during treatment. Similar findings were not observed in animals treated with 3 mcg/kg ACTIMMUNE.</p>
<p>Female mice receiving recombinant murine IFN-interferon gamma (rmuIFN-gamma) at 32 times the maximum recommended clinical dose of ACTIMMUNE for 4 weeks via intramuscular injection exhibited an increased incidence of atretic ovarian follicles.</p>
<p>Male cynomolgus monkeys treated intravenously for 4 weeks with 8 times the maximum recommended clinical dose of ACTIMMUNE exhibited decreased spermatogenesis. Male mice receiving rmuIFN-gamma at 32 times the maximum recommended clinical dose of ACTIMMUNE for 4 weeks via intramuscular injection exhibited decreased spermatogenesis. The impact of this finding on fertility is not known.</p>
<p>Male mice treated subcutaneously with rmuIFN-gamma from shortly after birth through puberty, with 280 times the maximum recommended clinical dose of ACTIMMUNE exhibited profound yet reversible decreases in sperm counts and fertility, and an increase in the number of abnormal sperm.</p>
<p>The clinical significance of these findings observed following treatment of mice with rmuIFN-gamma is uncertain.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Effects in <span class="product-label-link" type="condition" conceptid="4300478" conceptname="Chronic granulomatous disease">Chronic Granulomatous Disease</span> (CGD)</h2>
<p class="First">A randomized, double-blind, placebo-controlled trial of ACTIMMUNE (interferon gamma-1b) in patients with CGD, was performed to determine whether ACTIMMUNE administered subcutaneously on a three times weekly schedule could decrease the incidence of serious infectious episodes and improve existing infectious and inflammatory conditions in patients with CGD. One hundred twenty-eight eligible patients were enrolled in this trial including patients with different patterns of inheritance. Most patients received <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotics. Patients ranged in age from 1 to 44 years with the mean age being 14.6 years. The study was terminated early following demonstration of a highly statistically significant benefit of ACTIMMUNE therapy compared to placebo with respect to time to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (p=0.0036), the primary endpoint of the investigation. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was defined as a clinical event requiring hospitalization and the use of parenteral antibiotics. The final analysis provided further support for the primary endpoint (p=0.0006). There was a 67 percent reduction in relative risk of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients receiving ACTIMMUNE (n=63) compared to placebo (n=65). Additional supportive evidence of treatment benefit included a twofold reduction in the number of primary serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the ACTIMMUNE group (30 on placebo versus 14 on ACTIMMUNE, p=0.002) and the total number and rate of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including recurrent events (56 on placebo versus 20 on ACTIMMUNE, p=&lt;0.0001). Moreover, the length of hospitalization for the treatment of all clinical events provided evidence highly supportive of an ACTIMMUNE treatment benefit. Placebo patients required three times as many inpatient hospitalization days for treatment of clinical events compared to patients receiving ACTIMMUNE (1493 versus 497 total days, p=0.02). An ACTIMMUNE treatment benefit with respect to time to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was consistently demonstrated in all subgroup analyses according to stratification factors, including pattern of inheritance, use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotics, as well as age. There was a 67 percent reduction in relative risk of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients receiving ACTIMMUNE compared to placebo across all groups. The beneficial effect of ACTIMMUNE therapy was observed throughout the entire study, in which the mean duration of ACTIMMUNE administration was 8.9 months/patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Effects in Severe, Malignant Osteopetrosis (SMO)</h2>
<p class="First">A controlled, randomized trial in patients with SMO was conducted with ACTIMMUNE administered subcutaneously three times weekly. Sixteen patients were randomized to receive either ACTIMMUNE plus calcitriol (n=11), or calcitriol alone (n=5). Patients ranged in age from 1 month to 8 years, mean 1.5 years. Treatment failure was considered to be disease progression as defined by 1) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, 2) significant reduction in hemoglobin or platelet counts, 3) a serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> requiring antibiotics, or 4) a 50 dB decrease in hearing or progressive <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>. The median time to disease progression was significantly delayed in the ACTIMMUNE plus calcitriol arm versus calcitriol alone. In the treatment arm, the median was not reached. Based on the observed data, however, the median time to progression in this arm was at least 165 days versus a median of 65 days in the calcitriol alone arm. In an analysis which combined data from a second study, 19 of 24 patients treated with ACTIMMUNE plus or minus calcitriol for at least 6 months had reduced trabecular bone volume compared to baseline.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="S16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">ACTIMMUNE (interferon gamma-1b) is a sterile, clear, colorless solution filled in a single-use vial for subcutaneous injection. Each vial permits the extraction of up to 0.5 mL of ACTIMMUNE with additional volume to facilitate solution withdrawal. Each 0.5 mL of ACTIMMUNE contains: 100 mcg (2 million International Units) of interferon gamma-1b.</p>
<table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">NDC Number</th>
<th align="left">Size</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">42238-111-01</td>
<td align="left">One vial</td>
</tr>
<tr class="Last">
<td align="left">42238-111-12</td>
<td align="left">Cartons of 12 vials</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<p class="First">Store vials in the refrigerator at 2 to 8 °C (36 °F – 46 °F). <span class="Italics">Do Not Freeze. </span>Avoid excessive or vigorous <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. <span class="Italics">Do Not Shake</span>. An unused vial of ACTIMMUNE can be stored at room temperature up to 12 hours prior to use. Discard vials if not used within the 12 hour period. Do not return to the refrigerator.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient and/or their parents or caregivers to read the FDA-approved patient labeling (Information for Patient/Caregiver).</p>
<ul class="Disc">
<li>Inform patients and/or their parents or caregiver regarding the potential benefits and risks associated with treatment. If home use is determined to be desirable by the physician, instructions on appropriate use should be given, including review of the contents of the Information for Patient/ Caregiver. This information is intended to aid in the safe and effective use of the medication. It is not a disclosure of all possible adverse or intended effects.</li>
<li>If home use is prescribed, a puncture resistant container for the disposal of used syringes and needles should be used by the patient and/or parents or caregivers. Instruct patients thoroughly on the importance of proper disposal and caution the patient and/or patient or caregiver against any reuse of needles and syringes. The full container should be disposed of according to the directions provided by the physician.</li>
<li>Advise the patients and/or their parents or caregivers that the most common adverse reactions occurring with ACTIMMUNE therapy are "flu-like" or constitutional symptoms such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span> which may decrease in severity as treatment continues. Some of the "flu-like" symptoms may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may also be used to prevent or partially alleviate the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</li>
<li>Advise patients and/or their parents or caregivers that they may experience undesirable effects such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span> during treatment. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience any of these events, they should avoid potentially hazardous tasks such as driving or operating machinery. This effect may be enhanced by alcohol.</li>
</ul>
<p>Manufactured by:<br>Horizon Pharma Ireland Ltd.<br>Dublin, Ireland<br>U.S. License No. 2022</p>
<p>Distributed by:<br>HZNP USA Inc.<br>Roswell, GA 30076</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="IFP"></a><a name="section-16"></a><p></p>
<h1>Information for the Patient/Caregiver<br> ACTIMMUNE<span class="Sup">®</span> (Interferon gamma-1b)</h1>
<p class="First"><span class="Bold">DO NOT ADMINISTER <span class="Italics"> ACTIMMUNE </span> UNTIL YOUR PHYSICIAN HAS THOROUGHLY TRAINED YOU IN THE PROPER TECHNIQUES.</span></p>
<p><span class="Italics">ACTIMMUNE</span> is supplied in single-use vials. The unused portion of each vial should be disposed of as instructed by your physician. <span class="Bold">DO NOT SHAKE.</span></p>
<p>Your physician will tell you what size needle and syringe to use and also give you instructions on sterile technique. Keep all used syringes and needles out of the reach of children. Follow your physician's instructions on the safe disposal of used syringes and needles.</p>
<p><span class="Bold">MEASURING THE DOSE</span></p>
<p>In measuring the correct dose for injection, be sure to check that the <span class="Italics"> ACTIMMUNE</span> solution is clear. If the solution is cloudy or hazy, do not inject it, but return the <span class="Italics"> ACTIMMUNE </span> vial to your pharmacist or prescribing physician.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="45%">
<col align="left" valign="top" width="55%">
<tbody class="Headless">
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-01.jpg"></td>
<td align="left">
<span class="Bold">1.</span><br>Wash your hands thoroughly with soap and water before preparing the medication. This helps prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-02.jpg"></td>
<td align="left">
<span class="Bold">2.</span><br>Check the date on the <span class="Italics"> ACTIMMUNE </span> vial to be sure the drug has not expired.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-03.jpg"></td>
<td align="left">
<span class="Bold">3.</span><br>Remove the protective plastic cap and wipe the rubber stopper located on top of the <span class="Italics"> ACTIMMUNE</span> vial with an alcohol swab.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-04.jpg"></td>
<td align="left">
<span class="Bold">4.</span><br>Draw air into the syringe by pulling back on the plunger. The amount of air should be equal to the <span class="Italics"> ACTIMMUNE </span> dose.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-05.jpg"></td>
<td align="left">
<span class="Bold">5.</span><br>Remove and save the needle guard. Slowly insert the needle straight through the center of the rubber stopper into the <span class="Italics"> ACTIMMUNE </span> vial.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-06.jpg"></td>
<td align="left">
<span class="Bold">6.</span><br><span class="Bold">Gently </span> push the plunger to discharge the air into the vial.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-07.jpg"></td>
<td align="left">
<span class="Bold">7.</span><br>Turn the vial upside down with the syringe needle still in it and hold it in one hand. Be sure the tip of the needle is in the solution. Using your other hand <span class="Bold"> slowly </span> pull back on the plunger in a continuous motion until the correct amount of <span class="Italics"> ACTIMMUNE</span> solution is in the syringe.  Each vial contains enough <span class="Italics">ACTIMMUNE</span> for removal of up to 0.5 mL, with a small additional amount present for ease of withdrawal.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-08.jpg"></td>
<td align="left">
<span class="Bold">8.</span><br>Remove the needle from the <span class="Italics"> ACTIMMUNE </span> vial and replace the needle guard until time of administration or injection. Administration should be as soon after filling the syringe as possible; do not store <span class="Italics"> ACTIMMUNE </span> in the syringe.</td>
</tr>
<tr><td align="left" colspan="2"><span class="Bold">SELECTING THE INJECTION SITE</span></td></tr>
<tr><td align="left" colspan="2">Your doctor or nurse will teach you how to locate appropriate injection sites. It is very important that you rotate the site of an injection each time you give the medication. Even if you or your child develop a preference for one site – as often happens – you still should rotate the injection site.</td></tr>
<tr><td align="left" colspan="2">Following are the injection sites most often recommended:</td></tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-09.jpg"></td>
<td align="left"><ul class="Square"><li>Upper Arm</li></ul></td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-10.jpg"></td>
<td align="left"><ul class="Square"><li>Abdomen</li></ul></td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-11.jpg"></td>
<td align="left"><ul class="Square"><li>Thigh</li></ul></td>
</tr>
<tr><td align="left" colspan="2"><span class="Bold">GIVING THE MEDICATION</span></td></tr>
<tr><td align="left" colspan="2">Your doctor or nurse will provide you with hands-on training on how to give an injection. Needles and syringes should be used only once to insure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of both the needle and the syringe. The following is a review of the steps involved in giving the medication:</td></tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-12.jpg"></td>
<td align="left">
<span class="Bold">1.</span><br>Cleanse the injection site with an alcohol-saturated cotton ball or cotton swab.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-13.jpg"></td>
<td align="left">
<span class="Bold">2.</span><br>Remove the needle guard from the syringe filled with the proper dose of solution and hold the syringe the way you would hold a pencil. Double check that the correct amount of <span class="Italics"> ACTIMMUNE</span> solution is in the syringe.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-14.jpg"></td>
<td align="left">
<span class="Bold">3.</span><br>Squeeze the skin between your fingers before and during the injection. Insert the needle into the skin at a 45° angle with a quick, firm motion. This hurts less than pushing the needle in slowly.</td>
</tr>
<tr><td align="left" colspan="2">
<span class="Bold">4.</span><br>After the needle is in, pull back very slightly with one hand on the plunger to see if blood comes into the syringe. This is to be sure that the needle has not entered a blood vessel. If blood does come into the syringe, do not inject the <span class="Italics">ACTIMMUNE</span> solution. Withdraw the needle and insert at another location.</td></tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-15.jpg"></td>
<td align="left">
<span class="Bold">5.</span><br>If blood does not come into the syringe, slowly (within a few seconds) inject the solution by gently pushing the plunger until the syringe is empty.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-16.jpg"></td>
<td align="left">
<span class="Bold">6.</span><br>Withdraw the needle quickly, pulling it straight out, and apply pressure over the injection site with a dry gauze pad or cotton ball. A drop of blood may appear. Put a Band-Aid<span class="Sup">®</span> on the injection site if desired.</td>
</tr>
<tr>
<td align="left"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-17.jpg"></td>
<td align="left">
<span class="Bold">7.</span><br>To prevent injury, safely dispose of all used needles and syringes after a single use as instructed by your physician by following these simple steps:</td>
</tr>
<tr><td align="left" colspan="2"><ul class="Square">
<li>Place all used needles and syringes in a hard, plastic container with a screw-on cap, or a metal container with a plastic lid, such as a coffee can properly labeled as to content. If a metal container is used, cut a small hole in the plastic lid and tape the lid to the metal container. When the metal container is full, cover the hole with tape and throw it away. If a hard, plastic container is used, always screw the cap on tightly after each use. When the plastic container is full, tape around the cap and throw it away.</li>
<li>Do not use glass or clear, plastic containers, or any container that will be recycled or returned to a store.</li>
<li>Always store the container out of the reach of children.</li>
<li>Please check with your doctor, nurse or pharmacist for other suggestions. There may be special state and local laws that they will discuss with you.</li>
</ul></td></tr>
<tr><td align="left" colspan="2">
<span class="Bold">8.</span><br>Occasionally a problem may develop at the injection site. If you notice any of the following signs or symptoms, contact your doctor or nurse: 									<ul class="Square">
<li>A lump or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> that doesn't go away</li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span> that doesn't go away</li>
<li>Any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> at an injection site (pus, persistent <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, surrounding skin that is hot to the touch, persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after the injection)</li>
</ul>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1>STORAGE</h1>
<p class="First"><span class="Italics">ACTIMMUNE</span> (Interferon gamma-1b) must be refrigerated immediately. Refrigerate at 36° to 46° Fahrenheit (2° to 8° Centigrade). <span class="Bold"> DO NOT FREEZE.</span></p>
<p><span class="Italics">ACTIMMUNE </span> is supplied in single-use vials. The unused portion of each vial should be disposed of according to state and local regulations as instructed by your physician. If you have any questions, contact your physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Manufactured by:<br>Horizon Pharma Ireland Ltd.<br>Dublin, Ireland<br>US License No. 2022</p>
<p>Distributed by:<br>HZNP USA Inc.<br>Roswell, GA 30076</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 12 Single-use 5 mL Vial Carton</h1>
<p class="First">NDC 42238-111-12</p>
<p>KEEP REFRIGERATED</p>
<p><span class="Bold">ACTIMMUNE<span class="Sup">®</span></span><br>(Interferon gamma-1b)</p>
<p><span class="Bold">How supplied: </span>Each carton contains 12 single-use<br>vials of Interferon gamma-1b, <span class="Italics">ACTIMMUNE</span>.</p>
<p><span class="Bold">Contents: </span>Each 0.5 mL vial of <span class="Italics">ACTIMMUNE</span> contains<br><span class="Bold">100 mcg (2 million IU)</span> Interferon gamma-1b formulated<br>in 20 mg mannitol, 0.37 mg disodium succinate<br>hexahydrate, 0.14 mg succinic acid, 0.05 mg polysorbate<br>20 and Sterile Water for Injection for subcutaneous injection.<br><span class="Italics">ACTIMMUNE</span> contains no preservatives.</p>
<p><span class="Bold">Dosage and administration:</span> See<br>package insert for full prescribing<br>information. <span class="Italics">ACTIMMUNE</span> is<br>suitable for single-use only.<br>DO NOT SHAKE.</p>
<p><span class="Bold">Storage: </span>Refrigerate at<br>2° to 8°C/36° to 46°F.<br>DO NOT FREEZE.</p>
<div class="Figure"><img alt="Principal Display Panel - 12 Single-use 5 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=498b2231-65e8-4b27-947b-8d1f6f91289c&amp;name=actimmune-18.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTIMMUNE 		
					</strong><br><span class="contentTableReg">interferon gamma-1b injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42238-111</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Interferon gamma-1b</strong> (Interferon gamma-1b) </td>
<td class="formItem">Interferon gamma-1b</td>
<td class="formItem">100 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">20 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium succinate hexahydrate</strong></td>
<td class="formItem">0.37 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>succinic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 20</strong></td>
<td class="formItem">0.05 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42238-111-12</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42238-111-01</td>
<td class="formItem">0.5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103836</td>
<td class="formItem">12/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>HZNP USA, Inc.
							(969600589)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH &amp; Co KG</td>
<td class="formItem"></td>
<td class="formItem">340700520</td>
<td class="formItem">MANUFACTURE(42238-111)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td class="formItem"></td>
<td class="formItem">300010883</td>
<td class="formItem">API MANUFACTURE(42238-111)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bf71a33a-8d53-43f9-89c2-f39960eac1bc</div>
<div>Set id: 498b2231-65e8-4b27-947b-8d1f6f91289c</div>
<div>Version: 4</div>
<div>Effective Time: 20150904</div>
</div>
</div> <div class="DistributorName">HZNP USA, Inc.</div></p>
</body></html>
